At the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, three studies refined obesity and diabetes management across gastric physiology, diabetic foot ulcer (DFU) care, and endocrine effects of weight-loss pharmacotherapy.
Article Key Points
- Gastric emptying: higher BMI linked to faster T50 (beta=-0.86, p=0.01); faster with vs without dysglycemia
- Inforatio DFU RCT (n=100, Denmark): complete healing 24/49 vs 14/51; adjusted OR 3.01, 95% CI 1.20-7.58, p=0.02
- Inforatio reduced ulcer-related adverse events (HR 0.56, 95% CI 0.35-0.88); one-year amputations 6 vs 12, deaths 4 vs 5
- Tirzepatide (SURMOUNT-1): TSHB fell 19.4% at week 24 and 11.5% at week 72 (FDR p<0.001); partial rebound week 24-72
- SURMOUNT-5: tirzepatide and semaglutide produced comparable TSHB reductions; weight loss only weakly correlated (r=0.18)
- Evidence status: conference abstracts; full results have not yet been peer-reviewed
Gastric Emptying and Obesity: Higher BMI, Faster Emptying
Study design: Cross-sectional study of 163 adults with obesity (mean age 35.5 ± 1.0 years; 36% female). All participants underwent anthropometric assessment, a 75 g oral glucose tolerance test (OGTT), and lipid analysis. After ingestion of a 99mTc-DTPA-labeled semi-solid meal, gastric emptying rate was measured by scintigraphy.
Results: After multivariable adjustment, body mass index (BMI) was inversely correlated with half-emptying time (T50) (beta=-0.86, 95% confidence interval [CI] -1.51 to -0.21, p=0.01); higher BMI corresponded to faster gastric emptying. Individuals with obesity and diabetes showed faster gastric emptying than those with prediabetes or normal glucose tolerance (p<0.05). The authors noted that accelerated gastric emptying is associated with higher BMI in adults with obesity, though the underlying mechanism requires further investigation.
Inforatio Technique: Low-Cost Adjunct Improves DFU Healing
Study design: Multicenter, observer-blinded randomized clinical trial conducted at specialist wound care clinics across four hospitals in Denmark. Patients with non-infected, superficial DFU were randomized 1:1 to Inforatio every 3 weeks for 12 weeks plus standard care, or to standard care alone. Inforatio uses a 2 mm biopsy punch to make small incisions at the wound periphery, costs approximately 2.5 euros per use, takes 1-5 minutes, and can be performed at the bedside as part of routine wound care. The primary outcome was the proportion of ulcers achieving complete healing within 20 weeks, assessed by treatment-blinded observers from photographs.
Results: A total of 100 patients were randomized (Inforatio n=49; standard care n=51). Mean age was 64.4 years (SD 11.4); 85 were male; 83 had type 2 diabetes (T2D). Within 20 weeks, complete healing occurred in 24 patients in the Inforatio arm versus 14 in the standard care arm (adjusted odds ratio 3.01, 95% CI 1.20-7.58; p=0.02). Quality of life changes did not differ between groups. Serious adverse events occurred in 7 patients in the Inforatio arm versus 13 in the standard care arm (hazard ratio [HR] 0.56, 95% CI 0.24-1.29); ulcer-related adverse events occurred in 16 versus 30 (HR 0.56, 95% CI 0.35-0.88). During one-year follow-up, the Inforatio arm recorded 6 amputations and 4 deaths, versus 12 amputations and 5 deaths in the standard care arm.
The authors noted that Inforatio as an adjunct to standard care improved DFU healing and reduced ulcer-related adverse events, suggesting a potential role in resource-limited settings.
Tirzepatide Weight Loss and TSHB: Modest Reduction Without Clinical Relevance
Study design: Analysis based on the SURMOUNT program. In SURMOUNT-1 (SM-1, N=943), SURMOUNT-2 (SM-2, N=472), and SURMOUNT-5 (SM-5), fasting plasma proteins were measured at baseline, week 24, and week 72 using the Olink ExploreHT platform. The target was TSHB subunit protein. A repeated-measures mixed model was used, with age, sex, and baseline protein level as covariates; least-squares mean contrasts assessed protein levels at each time point. Significance was defined as Benjamini-Hochberg false discovery rate (FDR) <0.05.
Results: During tirzepatide treatment, TSHB in participants with obesity in SM-1 decreased by 19.4% from baseline to week 24 (95% CI 14.8%-23.7%; p=3.66x10^-14; FDR p=3.45x10^-13) and by 11.5% from baseline to week 72 (95% CI 6.42%-16.3%; p=1.85x10^-5; FDR p=8.74x10^-5). The partial rebound from week 24 to week 72 was statistically significant. SM-2 participants with obesity and T2D showed a similar pattern. SM-5 results showed that both tirzepatide and semaglutide were associated with TSHB reduction, with no significant between-group difference. In SM-1, the decrease was 21.94% in women versus 14.00% in men. The magnitude of weight loss correlated only weakly with TSHB reduction (SM-1 r=0.18, p=4.0x10^-8). As a contextual reference, an analysis of 51,243 UK Biobank (UKB) individuals showed that each 5 kg/m^2 BMI reduction was associated with only approximately 3% TSHB reduction (r=0.046, p=5.2x10^-25).
The authors noted that tirzepatide treatment is accompanied by TSHB reduction, but the magnitude is not clinically meaningful, and patients and clinicians should be aware of this change. The decrease exceeded what would be expected from BMI alone based on UKB cross-sectional data, possibly reflecting hypothalamic-pituitary-thyroid axis adaptation to weight loss.
Conclusion
Three studies refined understanding of obesity and diabetes across physiology, intervention, and pharmacotherapy. Gastric emptying was associated with obesity and dysglycemia and may participate in the underlying pathophysiology. Inforatio, a low-cost bedside adjunct, improved healing and ulcer-related events, and may offer an option in resource-limited environments. Tirzepatide was accompanied by a modest TSHB reduction without clinical relevance, suggesting the need for clinicians to monitor potential endocrine effects of weight-loss pharmacotherapy.